img:is([sizes=auto i],[sizes^="auto," i]){contain-intrinsic-size:3000px 1500px} /*# sourceURL=wp-img-auto-sizes-contain-inline-css */

ÂÒÂ×ÉçÇø

Skip to content

Federal and State Technology (FAST) Partnership

The U.S. Small Business Administration (SBA) announces the 2020 .Ìý provides one-year funding to organizations to execute state or regional programs that increase the number of SBIR/STTR proposals leading to an increase in the number of SBIR/STTR awards.

Prospective applicants are encouraged to refer to the above Notice of Funding Opportunity on  for more details, including matching-fund requirements, application and submission deadlines, and other information.Ìý The application period will close June 19, 2020.

 

Pre application webinar will be on May 15, 2020 from 3:00-4:00 p.m. EDT 

  • Web portion:
  • Audio: dial 202-765-1264 with code218771869# ()
  • Call notes will be posted on Grants.gov

 

The Notice of Funding Opportunity, Synopsis, Grants.gov Instructions, and Terms & Conditions will also be available shortly on .

NIBIB Announces Rapid Acceleration of Diagnostics (RADx) Program

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the NIH Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.

 

NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to  clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution.

 

Please see the , , and from Francis Collins for details.

UW Entrepreneurial Law Clinic Resources for COVID-19

The ÂÒÂ×ÉçÇø (a collaborator with WE-REACH) has put together a set of resources to help businesses grappling with COVID-19. In particular, they have several links for R&D funding and grants for Life Sciences businesses.

For the full list of Entrepreneurial Law Clinic resources, follow the .

Center for AIDS Research Resource Support

Informational Webinar: March 25, 2020 ()
Required Core Consultation Deadline: April 15, 2020
Application Deadline: April 22, 2020

±Ê³Ü°ù±è´Ç²õ±ð:ÌýTo encourage investigators, especially those junior or new to CFAR, to leverage existing CFAR services, data, and/or specimens for short-term, innovative HIV-related pilot projects that are likely to generate sufficient data for subsequent applications for future research funding.

Eligibility:

A Principal Investigator must:

1. Be a faculty member, senior post-doctoral fellow, or scientist at a UW/Fred Hutch CFAR affiliated institution, including the ÂÒÂ×ÉçÇø, Fred Hutch, Infectious Disease Research Institute (IDRI), Seattle Children’s, University of Hawai’i at Manoa, and affiliated international institutions.Ìý Applicants from affiliated non-U.S. institutions must have a primary mentor at one of the U.S.-based UW/Fred Hutch CFAR institutions named above.
2. Have attained a qualifying terminal degree (or equivalents), defined as follows:
  • PhD
  • MD
  • MBChB or MBBS, plus two years of research experience or training

3. Be a UW/Fred Hutch CFAR Member.

Funding:

A CFAR Core services voucher mechanism for up to $15,000 of direct costs per project, and projects must be completed within one year.Ìý The awards are intended to fund Core services in excess of what can routinely be provided by a Core,Ìýalthough up to 25% of the iCFAR budget can be used on non-Core expenses that are essential to the project. Those expenses can be in the categories that the National Institutes of Health deems .

°ä´Ç²Ô³Ù²¹³¦³ÙÌýcfardev@uw.edu with questions.

Unitaid to Fund $2MM for Oxygen Therapy Innovations

Unitaid, a partner of the and a funding arm of the WHO, has announced for innovations in the development of fit-for-purpose oxygen therapy for global health and access. Depending on the scope of the project, the funding range is between USD 500k-2M. The deadline is March 19th, 2020. Please follow the for details.